Minorities in US Ineligible for CFTR Modulators Due to Poorly Studied Mutations

Minorities in US Ineligible for CFTR Modulators Due to Poorly Studied Mutations

283963

Minorities in US Ineligible for CFTR Modulators Due to Poorly Studied Mutations

Individuals with cystic fibrosis (CF) from racial and ethnic minority groups in the U.S. are twice as likely to be ineligible for disease-modifying therapies than white patients, because their mutations are not known to be suited to approved treatments, a study reports. The resulting lack of treatment access exacerbates these groups’ already severe disease course and earlier mortality, its researchers wrote. The study, “Cystic Fibrosis Patients of Minority Race and Ethnicity Less Likely Eligible for…

You must be logged in to read/download the full post.